Condition: B-cell Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-Cell ALL, Childhood · Sponsor: Medical College of Wisconsin
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
This description comes directly from the study's public registry record.
Meredith Beversdorf, RN · 414-266-5891 · mbeversdorf@chw.org
Emily Ruszkiewicz, BS · 414-266-4092 · eruszkiewicz@mcw.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04746209